Zydus Cadila has received the final approval from the USFDA to market Acamprosate Calcium Delayed-Release Tablets, 333 mg. This medication is used for maintenance of abstinence from alcohol in patients with alcohol dependence.

The drug will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 1.35, or 0.3%, to trade at Rs 442.30. The total volume of shares traded was 25,969 at the BSE (9.33 a.m., Monday).